Monthly Regulatory Roundup — June 2026

The FDA issued substantially equivalent determinations for seven aesthetic devices in June: Sanhe's Intense Pulsed Light Therapy Device, Beijing Sano's LumiGlam Laser System, The Beauty Tech Group's CurrentBody Skin LED Multi Light Therapy Mask, Lumenis's MILAN System, F Care Systems' Veineo System, Eufoton's LASEmaR 1500, and Starmed's VIVA combo RF System. All are cleared for general and plastic surgery use. These clearances mean manufacturers can now legally market and distribute in the U.S. If you're considering purchasing or upgrading equipment, verify the 510(k) number on any device before purchase—it's your proof of FDA clearance. Check the FDA's 510(k) database (fda.gov/medical-devices) to confirm current status and any post-market conditions.

Payless Compounders, LLC issued a Class II recall of Semaglutide-Glycine-Cyanocobalamin Injectable (2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials) due to lack of assurance of sterility. The recall is ongoing. If your practice sources compounded semaglutide or GLP-1 blends from this compounder, stop use immediately and contact your supplier and patients. Verify your compounder's FDA registration and inspection history at fda.gov/drugs/human-drug-compounding. Request certificates of analysis and sterility testing documentation. Document your due diligence in writing—this protects you if a patient is harmed.

The FDA's General and Plastic Surgery Devices Panel has established a public docket and called for comments on dermal fillers—a rare move signaling potential regulatory changes. Multiple Federal Register notices indicate the agency is gathering stakeholder input on filler safety, efficacy, labeling, and classification. This is not immediate rulemaking, but it's a precursor. Action item: monitor fda.gov for the docket number and consider submitting comments if you have clinical or safety data. Prepare for possible new labeling requirements, post-market surveillance obligations, or reclassification timelines. Stay alert to industry associations' guidance on this process.

1. Audit your device inventory: confirm all equipment has valid 510(k) clearances or de novo approvals. 2. Review your compounding supplier relationships: verify FDA registration, request recent inspection reports, and confirm sterility protocols. 3. Discontinue use of any Payless Compounders products immediately and notify affected patients. 4. Document all device and drug sourcing decisions in writing for your compliance file. 5. Subscribe to FDA recall alerts (fda.gov/safety/recalls) and the Federal Register for your device categories. 6. If you market dermal fillers, begin tracking the FDA's filler docket—you may need to provide data or respond to new guidance.

No major state board enforcement actions or FTC warnings targeting medical aesthetics were reported in June. However, this is a calm before potential activity: state boards continue to scrutinize unlicensed injectors and off-label claims, and the FTC remains focused on unsubstantiated marketing of aesthetic outcomes. Maintain current state licensure, document informed consent for all procedures, and avoid guaranteeing results in advertising. If your state requires specific training or certification for injectables, audit your staff credentials now.

Expect the FDA dermal filler review to accelerate through summer. The agency may issue guidance, request additional data from manufacturers, or announce advisory committee meetings. Device clearances will likely continue at a steady pace. Compounding oversight remains a priority—more recalls are possible. State boards are entering mid-year audit cycles. Your best defense: maintain meticulous records of all device and drug sourcing, staff training, and patient consent. Subscribe to FDA updates and your state medical board's alerts. Join your professional association for early notice of regulatory changes.